Drugs / Lonaprisan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00555919 | Mar 2008 → Apr 2010 | breast cancer | Bayer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lonaprisan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00555919 ↗ |
| Known as | BAY86-5044 | “Lonaprisan (ZK 230211, BAY86-5044)” NCT00555919 ↗ |
| Known as | ZK 230211 | “Lonaprisan (ZK 230211, BAY86-5044)” NCT00555919 ↗ |
| Action | Inhibit | “Progesterone receptor antagonist” CHEMBL146032 ↗ |
| Modality | Small molecule | — CHEMBL146032 ↗ |
| Route | Oral | “25 mg daily oral treatment” NCT00555919 ↗ |
| Target | PGR | “Progesterone receptor antagonist” CHEMBL146032 ↗ |